メラノーマにおけるPD-1阻害の獲得耐性に関連する変異

Zaretskyら（Wed,）はこの問題を研究した。

www.synapsesocial.com/papers/69d6b4c1733a2b54c8aa80cf — DOI: https://doi.org/10.1056/nejmoa1604958

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy· 2011 · 2,107 citations
2. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression.· 1991 · 311 citations
3. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation· 2010 · 2,154 citations
4. Adaptive Immune Resistance: How Cancer Protects from Immune Attack· 2015 · 622 citations
5. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab· 2015 · 83 citations